 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | INO-4700 / GeneOne, Inovio, ChAdOx1 MERS / J&J, University of Oxford
Journal: Safety and immunogenicity of the ChAdOx1, MVA-MERS-S, and GLS-5300 DNA MERS-CoV vaccines. (Pubmed Central) - Apr 25, 2023
The findings showed that high doses of current MERS-CoV vaccine candidates conferred better immunogenicity than low doses and that there were no differences in the safety of the vaccines.
- ||| INO-4700 / GeneOne, Inovio
Trial completion: Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers (clinicaltrials.gov) - Dec 27, 2022
P2, N=192, Completed, Sponsor: Inovio Pharmaceuticals
The findings showed that high doses of current MERS-CoV vaccine candidates conferred better immunogenicity than low doses and that there were no differences in the safety of the vaccines. Active, not recruiting --> Completed
- ||| INO-4700 / GeneOne, Inovio
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers (clinicaltrials.gov) - Nov 21, 2022
P2, N=192, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=542 --> 192 | Trial completion date: Jun 2024 --> Nov 2022 | Trial primary completion date: Jun 2024 --> Nov 2022
- ||| INO-4700 / GeneOne, Inovio
Clinical: All the BigPharm mentioned in the article. Even talk about vax for MERS yet no mention of #INO-4700. How is this to be considered a reliable article? 100 days to crank out a vaccine yet 55 years to have the balls and be transparent to release the data? #🐃💩 (Twitter) - Dec 2, 2021
- || INO-4700 / GeneOne, Inovio
Trial completion date, Trial primary completion date: Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers (clinicaltrials.gov) - Aug 20, 2021
P2, N=542, Recruiting, Sponsor: Inovio Pharmaceuticals
Recruiting --> Active, not recruiting | N=542 --> 192 | Trial completion date: Jun 2024 --> Nov 2022 | Trial primary completion date: Jun 2024 --> Nov 2022 Trial completion date: Sep 2023 --> Jun 2024 | Trial primary completion date: Sep 2023 --> Jun 2024
- |||| INO-4700 / GeneOne, Inovio
Enrollment open: Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers (clinicaltrials.gov) - Jun 2, 2021
P2, N=542, Recruiting, Sponsor: Inovio Pharmaceuticals
Trial completion date: Sep 2023 --> Jun 2024 | Trial primary completion date: Sep 2023 --> Jun 2024 Not yet recruiting --> Recruiting
- ||||| INO-4700 / GeneOne, Inovio
New P2 trial: Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers (clinicaltrials.gov) - Oct 19, 2020
P2, N=542, Not yet recruiting, Sponsor: Inovio Pharmaceuticals
- || INO-4700 / Inovio, GeneOne
Clinical, P1 data, Journal: Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. (Pubmed Central) - Jun 15, 2020
P1
Immune responses were dose-independent, detected in more than 85% of participants after two vaccinations, and durable through 1 year of follow-up. The data support further development of the GLS-5300 vaccine, including additional studies to test the efficacy of GLS-5300 in a region endemic for MERS coronavirus.
- ||| INO-4700 / GeneOne, Inovio
Trial completion, Trial completion date, Trial primary completion date: Evaluate the Safety, Tolerability and Immunogenicity Study of GLS-5300 in Healthy Volunteers (clinicaltrials.gov) - May 27, 2020
P1/2, N=60, Completed, Sponsor: GeneOne Life Science, Inc.
The data support further development of the GLS-5300 vaccine, including additional studies to test the efficacy of GLS-5300 in a region endemic for MERS coronavirus. Active, not recruiting --> Completed | Trial completion date: Nov 2020 --> Apr 2020 | Trial primary completion date: Sep 2020 --> May 2019
- || INO-4700 / GeneOne, Inovio
Enrollment closed: Evaluate the Safety, Tolerability and Immunogenicity Study of GLS-5300 in Healthy Volunteers (clinicaltrials.gov) - Mar 27, 2019
P1/2, N=60, Active, not recruiting, Sponsor: GeneOne Life Science, Inc.
Active, not recruiting --> Completed | Trial completion date: Nov 2020 --> Apr 2020 | Trial primary completion date: Sep 2020 --> May 2019 Recruiting --> Active, not recruiting
- | INO-4700 / GeneOne, Inovio
New P1/2 trial: Evaluate the Safety, Tolerability and Immunogenicity Study of GLS-5300 in Healthy Volunteers (clinicaltrials.gov) - Oct 25, 2018
P1/2, N=60, Recruiting, Sponsor: GeneOne Life Science, Inc.
- | INO-4700 / GeneOne, Inovio
Trial completion: Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers (clinicaltrials.gov) - Aug 2, 2018
P1, N=75, Completed, Sponsor: GeneOne Life Science, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || INO-4700 / GeneOne, Inovio
Enrollment closed: Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers (clinicaltrials.gov) - Jul 27, 2016
P1, N=75, Active, not recruiting, Sponsor: GeneOne Life Science, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| INO-4700 / GeneOne, Inovio
Enrollment open: Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers (clinicaltrials.gov) - Feb 28, 2016
P1, N=75, Recruiting, Sponsor: GeneOne Life Science, Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| INO-4700 / GeneOne, Inovio
New P1 trial: Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers (clinicaltrials.gov) - Feb 1, 2016
P1, N=75, Not yet recruiting, Sponsor: GeneOne Life Science, Inc.